Testing for Bladder Cancer
Transforming Bladder Cancer Screening with Proactive Diagnostics
Bladder cancer is one of the most common urological cancers in the UK, yet early detection remains a significant challenge. Many cases are diagnosed only after symptoms such as blood in the urine or urinary changes become noticeable — signs that often appear once the disease has already progressed. Traditional diagnostic methods typically identify bladder cancer only after structural abnormalities are visible on imaging or cystoscopy.
Tzar Labs aims to shift this paradigm by introducing a proactive diagnostic approach that identifies cancer risk at the molecular level, long before visible changes occur.
The HrC test represents a new generation of bladder cancer screening — one that prioritises prevention, precision, and early action. By analysing cancer‑initiating cells circulating in the bloodstream, the test offers earlier and clearer insights into bladder cancer risk than conventional methods alone.
Current Methods for Diagnosing Bladder Cancer
Bladder cancer diagnosis in the UK typically involves several established tools used within NHS and private healthcare settings:
Urine Cytology
A laboratory test that examines urine samples for abnormal cells. Useful for high‑grade cancers but less reliable for early‑stage or low‑grade disease.
Cystoscopy
The gold‑standard diagnostic procedure, involving a camera inserted into the bladder to visually inspect the lining for tumours or abnormalities.
Ultrasound or CT Urogram
Imaging used to detect masses, thickening of the bladder wall, or other structural changes.
Biopsy
Tissue samples collected during cystoscopy to confirm malignancy and determine cancer type.
These methods are essential in improving outcomes, yet they remain reactive — they detect cancer only after visible changes occur.
Limitations of Conventional Bladder Cancer Screening
Despite their value, traditional diagnostic tools present several challenges that can delay or complicate early detection:
No Routine Screening Programme
Unlike breast or bowel cancer, there is no national screening programme for bladder cancer in the UK, meaning most cases are detected only after symptoms appear.
Early Symptoms Are Often Missed
Blood in the urine (haematuria) may be intermittent or mistaken for infection, while urinary frequency or discomfort can be attributed to benign conditions.
Detection Threshold
Imaging and cystoscopy can only identify tumours once they reach a detectable size. Early‑stage or flat lesions (such as carcinoma in situ) may be difficult to detect.
Invasiveness
Cystoscopy, while essential, is invasive and can cause discomfort, anxiety, and risk of infection.
False Reassurance
Normal urine tests or imaging do not always rule out early bladder cancer, as molecular changes often occur long before structural abnormalities appear.
These limitations highlight the need for a diagnostic tool that identifies cancer risk before a tumour forms or becomes visible.
The HrC Test: A Breakthrough in Early Bladder Cancer Detection
The HrC test introduces a transformative approach to bladder cancer screening by focusing on the earliest biological drivers of cancer. Instead of waiting for visible abnormalities or symptoms, the test isolates and analyses Cancer Stem Cells (CSCs) — the rare cells responsible for initiating cancer development.
A simple 12ml blood sample enables the HrC test to deliver:
A 12–18 Month Early Warning Window
Detection of cancer‑initiating molecular activity long before conventional imaging or cystoscopy can identify abnormalities.
High Sensitivity and Clear Results
With sensitivity above 90%, the test provides a definitive “Risk” or “No Risk” score, reducing uncertainty and eliminating ambiguous outcomes.
Reliable “Safe Zone” Assessment
A clear indication of “no risk” offers reassurance that bladder cancer is not present and is unlikely to develop within the next year.
This proactive approach empowers individuals with earlier insights and greater control over their long‑term health.
Comprehensive Cancer Screening Through a Single Test
Pan‑Cancer Detection for Complete Health Protection
Although this document focuses on bladder cancer, the HrC test is designed as a comprehensive pan‑cancer screening tool. Research shows that many major cancers originate from similar stem‑cell‑driven mechanisms. By analysing CSCs, the HrC test can screen for more than 60 different cancers through one blood draw.
Key Advantages Include:
Holistic Health Monitoring: Simultaneous assessment of bladder cancer risk alongside other major cancers such as Bowel, Breast, Cervical, Kidney, Leukaemia, Liver, Lung, Lymphoma, Ovarian, Pancreatic and Prostate.
- Actionable Insights: Early detection supports timely medical evaluation, lifestyle changes, and preventive strategies.
- One Test, Broad Coverage: A single, non‑invasive test that enhances long‑term health planning and peace of mind.
Tzar Labs’ mission is to support complete health protection through advanced, accurate, and proactive cancer detection.
About HrC | The Science Behind the Technology | Eligibility Checker | Start Your HrC Journey Here